Abstract
Demyelinating diseases, such as multiple sclerosis, are characterized by the loss of the myelin sheath around neurons, owing to inflammation and gliosis in the central nervous system (CNS). Current treatments therefore target anti-inflammatory mechanisms to impede or slow disease progression. The identification of a means to enhance axon myelination would present new therapeutic approaches to inhibit and possibly reverse disease progression. Previously, LRR and Ig domain–containing, Nogo receptor–interacting protein (LINGO-1) has been identified as an in vitro and in vivo negative regulator of oligodendrocyte differentiation and myelination. Here we show that loss of LINGO-1 function by Lingo1 gene knockout or by treatment with an antibody antagonist of LINGO-1 function leads to functional recovery from experimental autoimmune encephalomyelitis. This is reflected biologically by improved axonal integrity, as confirmed by magnetic resonance diffusion tensor imaging, and by newly formed myelin sheaths, as determined by electron microscopy. Antagonism of LINGO-1 or its pathway is therefore a promising approach for the treatment of demyelinating diseases of the CNS.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Trapp, B.D., Ransohoff, R.M., Fisher, E. & Rudick, R. Neurodegeneration in multiple sclerosis: relationship to neurological disability. Neuroscientist 5, 48–57 (1999).
Noseworthy, J.H., Gold, R. & Hartung, H.P. Treatment of multiple sclerosis: recent trials and future perspectives. Curr. Opin. Neurol. 12, 279–293 (1999).
Diem, R. et al. Combined therapy with methylprednisolone and erythropoietin in a model of multiple sclerosis. Brain 128, 375–385 (2005).
DuboisDalcq, M., ffrench-Constant, C. & Franklin, R.J.M. Enhancing central nervous system remyelination in multiple sclerosis. Neuron 48, 9–12 (2005).
Mi, S. et al. LINGO-1 is a component of the Nogo-66 receptor/p75 signaling complex. Nat. Neurosci. 7, 221–228 (2004).
Mi, S. et al. LINGO-1 negatively regulates myelination by oligodendrocytes. Nat. Neurosci. 8, 745–751 (2005).
Lee, X. et al. NGF regulates the expression of axonal LINGO-1 to inhibit oligodendrocyte differentiation and myelination. J. Neurosci. 27, 220–225 (2007).
Wekerle, H., Kojima, K., Lannes-Vieira, J., Lassmann, H. & Linington, C. Animal models. Ann. Neurol. 36 Suppl, S47–S53 (1994).
Kerschensteiner, M. et al. Remodeling of axonal connections contributes to recovery in an animal model of multiple sclerosis. J. Exp. Med. 200, 1027–1038 (2004).
Reynolds, R. et al. The response of NG-2 expressing oligodendrocyte progenitors to demyelination in MOG-EAE and MS. J. Neurocytol. 31, 523–536 (2002).
Ben-Hur, T. et al. Transplanted multipotential neural precursor cells migrate into the inflamed white matter in response to experimental autoimmune encephalomyelitis. Glia 41, 73–80 (2003).
Lubetzki, C., Williams, A. & Stankoff, B. Promoting repair in multiple sclerosis: problems and prospects. Curr. Opin. Neurol. 18, 237–244 (2005).
Ludwin, S.K. & Johnson, E. Evidence for a “dying-back” gliopathy in demyelinating disease. Ann. Neurol. 9, 301–305 (1981).
Lassmann, H., Bartsch, U., Montag, D. & Schachner, M. Dying-back oligodendrogliopathy: a late sequel of myelin-associated glycoprotein deficiency. Glia 19, 104–110 (1997).
Trapp, B.D. et al. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 338, 278–285 (1998).
Papadopoulos, D., Pham-Dinh, D. & Reynolds, R. Axon loss is responsible for chronic neurological deficit following inflammatory demyelination in the rat. Exp. Neurol. 197, 373–385 (2006).
Kornek, B. et al. Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am. J. Pathol. 157, 267–276 (2000).
Zhao, C., Fancy, S.P.J., Kotter, M.R., Li, W.W. & Franklin, R.J.M. Mechanisms of CNS remyelination—the key to therapeutic advances. J. Neurol. Sci. 233, 87–91 (2005).
Eager, K.B. & Kennett, R.H. The use of conventional antisera in the production of specific monoclonal antibodies. J. Immunol. Methods 64, 157–164 (1983).
Wu, W., Scott, D.E. & Reiter, R.J. Transplantation of mammalian pineal gland: studies of survival, revascularization, reinnervation, and recovery of function. Exp. Neurol. 122, 88–99 (1993).
Li, L. et al. Rescue of adult mouse motoneurons from injury-induced cell death by a glial cell line-derived neurotrophic factor (GDNF). Proc. Natl. Acad. Sci. USA 92, 9771–9775 (1995).
Hasan, K.M., Gupta, R.K., Santos, R.M., Wolinsky, J.S. & Narayana, P.A. Comparison of gradient encoding schemes for diffusion-tensor MRI. J. Magn. Reson. Imaging 13, 769–780 (2001).
Basser, P.J. & Pierpaoli, C. Microstructural and physiological features of tissues elucidated by quantitative-diffusion-tensor MRI. J. Magn. Reson. B. 111, 209–219 (1996).
Kim, J.H. et al. Detecting axon damage in spinal cord from a mouse model of multiple sclerosis. Neurobiol. Dis. 21, 626–632 (2006).
Author information
Authors and Affiliations
Corresponding authors
Supplementary information
Supplementary Text and Figures
Supplementary Figs. 1–5, Supplementary Methods (PDF 221 kb)
Rights and permissions
About this article
Cite this article
Mi, S., Hu, B., Hahm, K. et al. LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis. Nat Med 13, 1228–1233 (2007). https://doi.org/10.1038/nm1664
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm1664